New stock news | Listing imminent! Truly Health Medical passes examination, securing the first stock of Siasun Robot&Automation in the market!

date
23:21 12/06/2026
avatar
GMT Eight
Guangdong Zhenjiankang Medical Technology Development Co., Ltd. successfully completed the listing hearing for the Main Board of the Hong Kong Stock Exchange, with China International Capital Corporation Limited and DBS Group serving as joint sponsors.
According to the information disclosed by the Hong Kong Stock Exchange on June 12th, Guangdong Zhenjiankang Medical Technology Development Co., Ltd. (referred to as Zhenjiankang Medical) successfully completed the listing hearing on the HKEx 18A Main Board, with CICC and DBS Bank acting as joint sponsors. With the landing and delivery of multiple innovative surgical Siasun Robot & Automation products, Zhenjiankang Medical is expected to see a substantial turning point in equipment delivery and operating income by 2025, with annual revenue increasing significantly from 1.791 million yuan in 2024 to 12.178 million yuan. The commercialization realization capability has significantly improved. According to the prospectus, Zhenjiankang Medical is the pioneer in the domestic percutaneous puncture & ablation surgery Siasun Robot & Automation field, with a market share of 36.4% in China by 2025 (delivering 6 devices in 2025, including 2 TH-S, 1 TH-P, 1 TH-S Pro, and 2 TH-X MW). The latest prospectus shows that Zhenjiankang Medical has obtained eight Class III medical device registration certificates (including two innovative products approved through the Innovative Medical Management equipment special review process excluding consumables) and two Class II medical device registration certificates (excluding consumables), and has established an intelligent medical Siasun Robot & Automation product matrix based on "percutaneous puncture, precise treatment" as the core. It is worth noting that the core product developed independently by Zhenjiankang Medical, the puncture surgery navigation positioning system TH-S model, has been recognized by the Chinese National Medical Products Administration as "domestically innovative", while the key product navigation positioning microwave ablation system TH-X MW model has been recognized as "internationally innovative" by the Chinese National Medical Products Administration.